Trial Profile

A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SLATE 001 (Primary) ; TCR-transduced lymphocytes (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
Indications Advanced breast cancer; Colorectal cancer; Gastrointestinal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

06 Apr 2026 Planned End Date changed from 15 Jun 2033 to 20 Feb 2029.
06 Apr 2026 Planned primary completion date changed from 15 Jun 2031 to 20 Feb 2029.
31 Mar 2026 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com